These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. Borchers AT; Leibushor N; Cheema GS; Naguwa SM; Gershwin ME J Autoimmun; 2011 Dec; 37(4):273-88. PubMed ID: 21907543 [TBL] [Abstract][Full Text] [Related]
11. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Atzeni F; Sarzi-Puttini P; Doria A; Iaccarino L; Capsoni F Autoimmun Rev; 2005 Mar; 4(3):144-52. PubMed ID: 15823500 [TBL] [Abstract][Full Text] [Related]
12. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X; Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531 [TBL] [Abstract][Full Text] [Related]
13. How to manage infections in the era of biologics? Saraceno R; Chimenti S Dermatol Ther; 2008; 21(3):180-6. PubMed ID: 18564248 [TBL] [Abstract][Full Text] [Related]